These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 11430421

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
    Pro B, Lozano R, Ajani JA.
    Invest New Drugs; 2001; 19(4):341-3. PubMed ID: 11561696
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
    Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D.
    J Natl Cancer Inst; 1994 Mar 16; 86(6):446-9. PubMed ID: 8120919
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
    Hoff PM, Saragiotto DF, Barrios CH, del Giglio A, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella Mdo S, Passos VQ, Chinen RN, van Eyll B.
    J Clin Oncol; 2014 Apr 01; 32(10):1006-11. PubMed ID: 24516038
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
    Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri MA, Cipolla C, Florena M.
    Anticancer Drugs; 1993 Aug 01; 4(4):443-5. PubMed ID: 8400346
    [Abstract] [Full Text] [Related]

  • 11. [Chemotherapy-induced diarrhea].
    Kobayashi K.
    Gan To Kagaku Ryoho; 2003 Jun 01; 30(6):765-71. PubMed ID: 12852342
    [Abstract] [Full Text] [Related]

  • 12. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
    Couteau C, Yakendji K, Terret C, Goncalves E, Armand JP.
    Bull Cancer; 1996 Jan 01; 83(1):3-10. PubMed ID: 8672854
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
    Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ.
    J Clin Oncol; 2004 Nov 01; 22(21):4410-7. PubMed ID: 15514383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E, Karaoglu A.
    Oncology; 2006 Nov 01; 71(5-6):354-60. PubMed ID: 17873499
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 01; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

  • 20. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
    Cascinu S, Fedeli A, Fedeli SL, Catalano G.
    J Clin Oncol; 1993 Jan 01; 11(1):148-51. PubMed ID: 8418225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.